(Q38621223)

consensus development conference proceedings

4 September 2017

1 reference

27 October 2020

1 reference

1 reference

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma (English)

1 reference

Erratum to: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma

4 September 2017

1 reference

27 October 2020

1 reference

3 references

25 June 2019

29 May 2020

27 October 2020

2 references

27 October 2020

corrigendum / erratum

0 references

author name string

Ashish M Kamat

1

1 reference

4 September 2017

Joaquim Bellmunt

2

1 reference

4 September 2017

Matthew D Galsky

3

1 reference

4 September 2017

Badrinath R Konety

4

1 reference

4 September 2017

Donald L Lamm

5

1 reference

4 September 2017

David Langham

6

1 reference

4 September 2017

Cheryl T Lee

7

1 reference

4 September 2017

Matthew I Milowsky

8

1 reference

4 September 2017

Michael A O'Donnell

9

1 reference

4 September 2017

Peter H O'Donnell

10

1 reference

4 September 2017

Daniel P Petrylak

11

1 reference

4 September 2017

Padmanee Sharma

12

1 reference

4 September 2017

Eila C Skinner

13

1 reference

4 September 2017

Guru Sonpavde

14

1 reference

4 September 2017

John A Taylor

15

1 reference

4 September 2017

Prasanth Abraham

16

1 reference

4 September 2017

Jonathan E Rosenberg

17

1 reference

4 September 2017

language of work or name

1 reference

15 August 2017

7 references

Journal for Immunotherapy of Cancer

4 September 2017

3 April 2019

22 April 2019

25 June 2019

29 May 2020

9 September 2020

27 October 2020

6 references

4 September 2017

3 April 2019

22 April 2019

25 June 2019

9 September 2020

27 October 2020

5

1 reference

4 September 2017

page(s)

68

1 reference

Creative Commons Attribution 4.0 International

4 September 2017

copyright license

5 references

3 April 2019

22 April 2019

25 June 2019

29 May 2020

on focus list of Wikimedia project

27 October 2020

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

Elements of cancer immunity and the cancer-immune set point

1 reference

https://api.crossref.org/works/10.1186%2FS40425-017-0271-0

Immune therapies in non-muscle invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40425-017-0271-0

21 January 2018

Cancer statistics, 2016

1 reference

https://api.crossref.org/works/10.1186%2FS40425-017-0271-0

Immune response following intravesical bacillus Calmette-Guerin instillations in superficial bladder cancer: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40425-017-0271-0

The mechanism of action of BCG therapy for bladder cancer--a current perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40425-017-0271-0

A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40425-017-0271-0

ICUD-EAU International Consultation on Bladder Cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40425-017-0271-0

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40425-017-0271-0

Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40425-017-0271-0

Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40425-017-0271-0

Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40425-017-0271-0

Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40425-017-0271-0

The future of drug development in urothelial cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40425-017-0271-0

The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40425-017-0271-0

Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40425-017-0271-0

Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40425-017-0271-0

Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40425-017-0271-0

Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40425-017-0271-0

Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 t

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40425-017-0271-0

Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Car

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40425-017-0271-0

Strategies for optimizing bacillus Calmette-Guérin

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40425-017-0271-0

Combination of Intravesical Chemotherapy and Bacillus Calmette-Guerin Versus Bacillus Calmette-Guerin Monotherapy in Intermediate- and High-risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40425-017-0271-0

Bacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40425-017-0271-0

Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40425-017-0271-0

Safety and efficacy of intravesical bacillus Calmette-Guérin plus interferon α-2b therapy for nonmuscle invasive bladder cancer in patients with prosthetic devices.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40425-017-0271-0

Recognition and treatment of BCG failure in bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40425-017-0271-0

Clinical utility of fluorescent in situ hybridization for the surveillance of bladder cancer patients treated with bacillus Calmette-Guérin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40425-017-0271-0

Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40425-017-0271-0

Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40425-017-0271-0

Risk prediction scores for recurrence and progression of non-muscle invasive bladder cancer: an international validation in primary tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40425-017-0271-0

Comparison of expected treatment outcomes, obtained using risk models and international guidelines, with observed treatment outcomes in a Dutch cohort of patients with non-muscle-invasive bladder cancer treated with intravesical chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40425-017-0271-0

Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guérin

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40425-017-0271-0

The origin, evolution, and principles of patient navigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40425-017-0271-0

Impact of patient navigation on timely cancer care: the Patient Navigation Research Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40425-017-0271-0

Nurse navigators in early cancer care: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40425-017-0271-0

Compliance with guidelines for patients with bladder cancer: variation in the delivery of care

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40425-017-0271-0

Use of radical cystectomy for patients with invasive bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40425-017-0271-0

Muscle invasive bladder cancer: examining survivor burden and unmet needs

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40425-017-0271-0

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40425-017-0271-0

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40425-017-0271-0

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40425-017-0271-0

Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40425-017-0271-0

PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40425-017-0271-0

Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40425-017-0271-0

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40425-017-0271-0

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5557323

Prophylactic intravesical chemotherapy decreases bladder tumor recurrence after nephroureterectomy for primary upper tract urothelial carcinoma: A systematic review and meta-analysis

4 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5557323

Reflex fluorescence in situ hybridization assay for suspicious urinary cytology in patients with bladder cancer with negative surveillance cystoscopy

4 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5557323

Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. 1976.

4 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5557323

Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study

4 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5557323

The effect of lubricants on viability of bacillus Calmette-Guerin for intravesical immunotherapy against bladder carcinoma.

4 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5557323

Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer.

4 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5557323

Intravesical bacille Calmette-Guérin (BCG) in immunologically compromised patients with bladder cancer

4 November 2018

1 reference

12 December 2020

Sequential bacillus Calmette-Guérin/Electromotive Drug Administration of Mitomycin C as the Standard Intravesical Regimen in High Risk Nonmuscle Invasive Bladder Cancer: 2-Year Outcomes

1 reference

12 December 2020

Extravesical involvement in patients with bladder carcinoma in situ: biological and therapy implications

1 reference

12 December 2020

Short-term administration of prulifloxacin in patients with nonmuscle-invasive bladder cancer: an effective option for the prevention of bacillus Calmette-Guérin-induced toxicity?

1 reference

12 December 2020

Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of mainte

1 reference

12 December 2020

Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: a report from the Bladder Cancer Advocacy Network Clinical Trials Working Group

1 reference

12 December 2020

Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials

1 reference

12 December 2020

Intravesical bacillus Calmette-Guérin outcomes in patients with bladder cancer and asymptomatic bacteriuria

1 reference

12 December 2020

Factors affecting response to bacillus Calmette-Guérin plus interferon for urothelial carcinoma in situ

1 reference

12 December 2020

The Effect of Ofloxacin on Bacillus Calmette-Guerin Induced Toxicity in Patients With Superficial Bladder Cancer: Results of a Randomized, Prospective, Double-Blind, Placebo Controlled, Multicenter Study

1 reference

12 December 2020

Long-term results of maintenance treatment of mitomycin C or alternating mitomycin C and bacillus Calmette-Guérin instillation therapy of patients with carcinoma in situ of the bladder: a subgroup analysis of the prospective FinnBladder 2 study with

1 reference

12 December 2020

10.1186/S40425-017-0271-0

Identifiers

DOI

1 reference

Dimensions Publication ID

4 September 2017

1091167162

0 references

PMC publication ID

5557323

0 references

28807024

1 reference